Cel Sci Corporation (CVM)

[MyAlias1]

Yeah I don't get the lack of anticipation ...

1. Several Cytokines have been approved in cancer immunotherapy.
2. National Institute of Health has identified those required to reject tumors.
3. Multikine does not have the safety problem that several cytokine based trials have run into.
4. Phase 2 10.5% of patients no remaining cancer cells after 3 wks Multikine.
5. Phase 2 remaining patients had ~50% average reduction in number of cancer cells after 3 wks Multikine.
6. Phase 2 Pathology
7. Phase 2 CD4/CD8 ratio

I understand that a small cap has had its share of issues and then some getting to this point and the binary nature of the data. It seems odd to me to think that all bets have been placed.